Japan Next-generation Sequencing Market (2026-2031)
The Japan Next-generation Sequencing Market was valued at $401.2 Million in 2026 and projected to reach to $756 Million by 2031, representing a compound annual growth rate of 13.5%. Japan's next-generation sequencing market is positioned for sustained growth through 2031, driven by the nation's aging population and increasing healthcare expenditure on advanced diagnostics.
Japan Next-generation Sequencing Market Trends and Insights
- Japan's healthcare sector is increasingly adopting NGS technologies for precision medicine, cancer diagnostics, and rare disease identification, driving sustained market growth.
- The 13.5% compound annual growth rate reflects Japan's aging population, rising healthcare expenditure, and strong government support for genomic research initiatives. Japan's NGS market benefits from advanced healthcare infrastructure and significant investments in biotechnology research.
- Japan's pharmaceutical and diagnostic companies are integrating NGS into clinical workflows, particularly in oncology and personalized medicine applications.
- Between 2026 and 2031, Japan is expected to see accelerated adoption of NGS platforms across academic medical centers, hospitals, and private diagnostic laboratories, supported by regulatory frameworks and reimbursement policies favoring genomic testing..
Key Market Statistics
- CAGR (2026-2031) 13.5% CAGR
- Market Size, 2026 ~USD 401.2 Million
- Forecast, 2031 ~USD 756 Million
- Country Japan
Japan Next-generation Sequencing Market Overview
Market Valuation Growth :
Japan's NGS market is valued at $401.2 million in 2026 and is projected to expand to $756.0 million by 2031, representing an 88% increase over the five-year forecast period.
Aging Population Driving Adoption :
Japan's rapidly aging demographic is accelerating NGS adoption for age-related disease diagnostics, cancer screening, and personalized treatment planning, supporting the 13.5% CAGR.
Precision Medicine Integration :
Japanese healthcare providers are increasingly integrating NGS into precision medicine workflows, enabling targeted therapies and improved patient outcomes across oncology and rare genetic disorders.
Outpacing Global Growth :
While Japan's 13.5% CAGR is slightly below the global 14.5% rate, the market demonstrates strong localized momentum driven by regulatory support and healthcare infrastructure investments.
Japan Next-generation Sequencing Market Dynamics
- Government initiatives promoting precision medicine and genomic research are creating favorable conditions for NGS technology adoption across hospitals, diagnostic laboratories, and research institutions.
- The market benefits from Japan's strong healthcare infrastructure and high patient awareness of genetic testing benefits. Key growth catalysts include expanding cancer genomics applications, rising rare disease diagnosis demand, and integration of NGS into routine clinical practice.
- Japanese pharmaceutical companies are investing heavily in companion diagnostics, further propelling market expansion.
- Competitive pricing pressures and technological advancements will continue to drive accessibility, while regulatory frameworks supporting genomic data management will enhance market confidence and institutional adoption rates..
Related Ecosystem
Key Takeaways
- Japan's NGS market is valued at $401.2 million in 2026 and will nearly double to $756.0 million by 2031, representing a 13.5% CAGR.
- Japan's aging population and rising cancer incidence are primary drivers of NGS adoption in clinical diagnostics and precision oncology.
- Japan's government initiatives and research funding support genomic medicine development, accelerating NGS platform integration across healthcare institutions.
- Japan's diagnostic laboratories and hospitals are increasingly implementing NGS for rare disease diagnosis and personalized treatment planning through 2031.
Next-generation Sequencing Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2026 |
| Fastest Growing Segment | SERVICES (Offering) |
| Forecast Period | 2026–2031 |
| Growth Rate | CAGR of 14.5% from 2026 to 2031 |
| Largest Segment | PRODUCTS (Offering) |
| Market Size Base Year (Billions) | ~USD 13.93 (2026) |
| Revenue Forecast (Billions) | ~USD 27.41 (2031) |
| Segments Covered | Offering, Type, Technology, Workflow, End User, Application |
Japan Next-generation Sequencing Market Report Segmentation
6 segment dimensions are covered across the global market.
By Offering
- Products
- Services
By Type
- Bioinformatics Tools
- Cancer Diagnostics
- Consumables
- Data Analysis Services
- Data Analysis Software & Workbenches
- Data Storage & Management Services
- Data Visualization & Interpretation Services
- Data Visualization Tools
- Illumina
- Infectious Disease Diagnostics
- Library Preparation & Target Enrichment Services
- Library Preparation Kits & Reagents
- Library Preparation Platforms
- Miniseq/Iseq
- Miseq/ Miseq I100
- Nextseq 1K/2K And 550
- Novaseq 6000
- Novaseq Series (X/ X Plus)
- Other Bioinformatics Tools
- Other Consumables
- Other Diagnostic Applications
- Other Drug Discovery & Development Applications
- Other Sequencing Platforms
- Oxford Nanopore Technologies
- Pacbio
- Pharmacogenomics
- Platforms
- Quality Control Services
- Reproductive Health Diagnostics
- Sample Preparation Services
- Sequencing Kits & Reagents
- Sequencing Platforms
- Thermo Fisher Scientific
By Technology
- Ion Semiconductor Sequencing
- Nanopore Sequencing
- Other Sequencing Technologies
- Sequencing By Synthesis
- Smrt Sequencing
By Workflow
- Data Analysis
- Presequencing
- Sequencing
By End User
- Academic & Research Institutes
- Clinical & Diagnostic Laboratories
- Hospitals & Clinical Laboratories
- Other End Users
- Pharmaceutical & Biotechnology Companies
By Application
- Agriculture & Animal Research
- Diagnostics
- Drug Discovery & Development
- Other Applications
Target Audience
- Diagnostic Laboratory Operators : Japanese diagnostic labs need market data to assess NGS service expansion opportunities, competitive positioning, and investment requirements for genomic testing infrastructure in a growing market.
- Medical Device & IVD Manufacturers : NGS equipment and reagent suppliers require Japan-specific market intelligence to guide product localization, pricing strategies, and distribution partnerships in this high-growth healthcare market.
- Pharmaceutical & Biotech Companies : Japanese and international pharma firms need insights on companion diagnostic opportunities, precision medicine adoption rates, and clinical trial recruitment potential in Japan's NGS ecosystem.
- Healthcare System Administrators : Hospital networks and healthcare policy makers require market data to inform NGS service integration decisions, budget allocation, and reimbursement strategy development for genomic testing.
- Investment & Venture Capital Firms : Investors targeting Japan's healthcare sector need comprehensive market analysis to identify high-growth NGS companies, assess market timing, and evaluate portfolio opportunities in genomics.
Key Companies in the Japan Next-generation Sequencing Market
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| DNA LINK | South Korea | Public Company | Whole genome and De Novo sequencing,Whole exome and targeted sequencing,Transcriptome and single-cell RNA sequencing, |
| WUXI APPTEC | China | Public Company | WuXi Chemistry (small molecules, oligos, peptides, conjugates),WuXi Testing (toxicology, DMPK, bioanalytical, other lab testing),WuXi Biology (discovery biology, target-to-candidate services), |
| THERAGEN ETEX CO., LTD. | South Korea | Public Company | Circulatory and metabolic drugs,Respiratory and digestive therapies,Antibiotics and antifungals, |
| SYSMEX CORPORATION | Japan | Public Company | Hematology analyzers and reagents (XN-Series, XN-V, ProCyte Dx),Coagulation diagnostics,Blood gas, electrolyte, and urinalysis systems, |
| GENOMICS BIOSCI & TECH. CO., LTD. | Taiwan | Public Company | Clinical testing (reproductive health and cancer),Sequencing, synthesis, genomics and proteomics services,CDMO (contract development and manufacturing), |
| INTEGRAGEN SA | France | Public Company | Genomic pharma and research sequencing services (oncology and rare disease),MERCURY oncology interpretation platform,Galileo RNA-Seq exploration and related analytics, |
| CENTOGENE AG | Germany | Public Company | Genetic sequencing and diagnostics (WES, WGS, NGS assays including NEW CentoGenome),Multiomic solutions (CENTOGENE MOx 2.0 and biochemical/RNA integration),Pharma solutions (target/drug screening, clinical development, market access, patient recruitment), |
| PERSONALIS, INC. | United States | Public Company | Pharma and biopharma services (ImmunoID NeXT, WES/WGS, translational research and clinical trials),MRD and therapy monitoring (NeXT Personal, NeXT Personal Dx),Clinical tumor profiling and Dx (NeXT Dx and related physician-ordered tests), |
| BIOMERIEUX S.A. | France | Public Company | Clinical microbiology (culture media, VITEK, VIRTUO, ETEST, API, VITEK REVEAL),Syndromic and molecular diagnostics (BIOFIRE, SPOTFIRE, ARGENE, EMAG/NUCLISENS),Immunoassays and CLIA (VIDAS, Hybiome), |
| ILLUMINA, INC. | United States | Public Company | Sequencing instruments,Sequencing consumables (reagents, flow cells, library prep),Array-based instruments and consumables, |
| THERMO FISHER SCIENTIFIC INC. | United States | Public Company | Life Sciences Solutions,Analytical Instruments,Specialty Diagnostics, |
| AGILENT TECHNOLOGIES, INC. | United States | Public Company | Life Sciences and Diagnostics Markets,Agilent CrossLab,Applied Markets, |
| QIAGEN | Netherlands | Public Company | Sample technology consumables and instruments,Immune response and infectious disease diagnostics,Oncology and sexual & reproductive health assays, |
| DANAHER CORPORATION | United States | Public Company | Biotechnology (bioprocessing and related solutions),Life Sciences (instruments, genomics, and reagents),Diagnostics (clinical instruments and consumables), |
| REVVITY | United States | Public Company | Diagnostics instruments and reagents (prenatal, neonatal, infectious disease, specialty immunodiagnostics),Life science reagents and assay platforms (immunology, cell analysis, proteomics),Genomic workflows and NGS-related tools, |
| EUROFINS SCIENTIFIC | Luxembourg | Public Company | Food and Feed Testing, Assurance, and Certification,Environment and Maritime Testing,Biopharma Testing and PSS Insourcing, |
| PACBIO | United States | Public Company | Long-read instruments (Revio, Sequel, Vega),Long-read consumables and SMRT reagents,Short-read sequencing (Onso) and related consumables, |
| OXFORD NANOPORE TECHNOLOGIES PLC | United Kingdom | Public Company | PromethION systems and consumables,MinION and portable platforms,GridION and mid-throughput systems, |
| TAKARA BIO INC. | Japan | Private Company | Genetic and cellular research reagents,Instruments (PCR and cellular analysis devices),In vitro diagnostics (including COVID-19 testing), |
| BD | United States | Public Company | Medical Essentials (vascular access, syringes, needles, sharps, enteral),Connected Care (infusion therapy, medication management, pharmacy automation, informatics),BioPharma Systems (prefillable drug delivery systems), |
| 10X GENOMICS | United States | Public Company | Chromium instruments,Chromium consumables & kits (incl. QuantumScale),Visium spatial platform (instruments, slides, assays), |
DNA LINK
DNA LINK is a South Korean public company founded in 2000 with 84 employees, operating in the genomics and biotechnology sector.
WUXI APPTEC
WUXI APPTEC is a Chinese public company founded in 2000 with 33,834 employees, providing pharmaceutical research and development services.
THERAGEN ETEX CO., LTD.
THERAGEN ETEX CO., LTD. is a South Korean public company founded in 1987 with 224 employees, specializing in genomics and genetic testing.
SYSMEX CORPORATION
SYSMEX CORPORATION is a Japanese public company founded in 1968 with 10,861 employees, providing diagnostic and laboratory equipment solutions.
GENOMICS BIOSCI & TECH. CO., LTD.
GENOMICS BIOSCI & TECH. CO., LTD. is a Taiwanese public company founded in 2001, operating in the genomics and biotechnology industry.
INTEGRAGEN SA
INTEGRAGEN SA is a French public company founded in 2000 with 37 employees, specializing in genomics and genetic analysis.
CENTOGENE AG
CENTOGENE AG is a German public company founded in 2006 with 384 employees, providing genetic testing and diagnostic services.
PERSONALIS, INC.
PERSONALIS, INC. is a United States-based public company founded in 2011 with 260 employees, specializing in genomic sequencing and analysis.
BIOMERIEUX S.A.
BIOMERIEUX S.A. is a French public company founded in 1963 with 14,894 employees, providing in vitro diagnostics and microbiology solutions.
ILLUMINA, INC.
ILLUMINA, INC. is a United States-based public company founded in 1998 with 8,625 employees, a leading provider of DNA sequencing and genetic analysis platforms.
THERMO FISHER SCIENTIFIC INC.
THERMO FISHER SCIENTIFIC INC. is a United States-based public company founded in 1956 with 125,000 employees, providing life sciences research and diagnostic products and services.
AGILENT TECHNOLOGIES, INC.
AGILENT TECHNOLOGIES, INC. is a United States-based public company founded in 1999 with 18,000 employees, offering analytical instruments and life sciences solutions.
QIAGEN
QIAGEN is a Netherlands-based public company founded in 1984 with 5,500 employees, providing molecular diagnostics and life sciences research tools.
DANAHER CORPORATION
DANAHER CORPORATION is a United States-based public company founded in 1969 with 59,000 employees, operating a diversified conglomerate including life sciences and diagnostics.
REVVITY
REVVITY is a United States-based public company founded in 1937 with 11,000 employees, providing analytical instruments and life sciences solutions.
EUROFINS SCIENTIFIC
EUROFINS SCIENTIFIC is a Luxembourg-based public company founded in 1987 with 65,694 employees, providing laboratory testing and scientific services globally.
PACBIO
PACBIO is a United States-based public company founded in 2000 with 485 employees, specializing in long-read DNA sequencing technology.
OXFORD NANOPORE TECHNOLOGIES PLC
OXFORD NANOPORE TECHNOLOGIES PLC is a United Kingdom-based public company founded in 2005 with 1,316 employees, developing nanopore-based DNA and RNA sequencing technology.
TAKARA BIO INC.
TAKARA BIO INC. is a Japanese private company founded in 2002 with 1,779 employees, providing biotechnology products and services for research and diagnostics.
BD
BD is a United States-based public company founded in 1897 with 72,000 employees, providing medical devices, diagnostics, and life sciences solutions.
10X GENOMICS
10X GENOMICS is a United States-based public company founded in 2012 with 1,178 employees, developing single-cell and spatial genomics technologies.
Reasons to Buy this Report
- Japan-Specific Market Sizing : Access precise valuation data for Japan's NGS market with verified 2026 baseline ($401.2M) and 2031 forecast ($756.0M), enabling accurate financial planning and investment decisions for Japan-focused strategies.
- Competitive Landscape Intelligence : Understand Japan's unique competitive dynamics, local player positioning, and market consolidation trends specific to the Japanese healthcare system and regulatory environment.
- Growth Driver Analysis : Identify Japan-specific growth catalysts including aging population demographics, government precision medicine initiatives, and healthcare reimbursement policies driving the 13.5% CAGR.
- Clinical Application Insights : Gain detailed understanding of NGS adoption patterns across Japanese oncology, rare disease diagnosis, and personalized medicine segments with localized clinical evidence and case studies.
- Strategic Market Entry Planning : Develop informed Japan market entry strategies with insights on regulatory pathways, reimbursement frameworks, key opinion leaders, and partnership opportunities in the Japanese healthcare ecosystem.
Frequently asked questions
What is the current size of Japan's next-generation sequencing market?
Japan's NGS market was valued at $401.2 million in 2026 and is projected to grow to $756.0 million by 2031.
What is the expected growth rate for Japan's NGS market?
Japan's NGS market is expected to grow at a compound annual growth rate (CAGR) of 13.5% from 2026 to 2031.
What are the primary drivers of NGS adoption in Japan?
Japan's NGS adoption is driven by an aging population, rising cancer prevalence, government genomic research initiatives, and increasing integration of precision medicine in clinical practice.
Which healthcare segments in Japan are adopting NGS technology?
Japan's academic medical centers, hospitals, private diagnostic laboratories, and pharmaceutical companies are actively adopting NGS for oncology, rare disease diagnosis, and personalized medicine applications.
How does Japan's NGS market compare to global trends?
Japan's NGS market growth rate of 13.5% is slightly below the global CAGR of 14.5%, reflecting Japan's mature healthcare infrastructure and selective adoption patterns in precision diagnostics.
RESEARCH METHODOLOGY
This study of the next-generation sequencing market relied on secondary sources, directories, and databases to gather pertinent information. To collect and validate key qualitative and quantitative data and to evaluate market growth prospects, in-depth interviews were conducted with numerous primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives from key market players, and industry consultants. After estimating the next-generation sequencing market using several research strategies, the final market size was derived by triangulating data from primary research.
Secondary Research
Secondary sources for this research study include publications from government sources. These include the Centers for Disease Control and Prevention (CDC), the US Food and Drug Administration (FDA), the World Health Organization (WHO), the American Cancer Society (ACS), the National Center for Biotechnology Information (NCBI), the National Institutes of Health (NIH), the National Human Genome Research Institute (NHGRI), the International Agency for Research on Cancer (IARC), the National Institute for Infectious Diseases (IRCCS), the Association for Clinical Genomic Science (ACGS), the American Society of Human Genetics (ASHG), the European Society of Human Genetics (ESHG), the Asia Pacific Society of Human Genetics (APSHG), Nature Reviews Genetics, Nature Methods, the Biotechnology and Biological Sciences Research Council (BBSRC), the Organisation for Economic Co-operation and Development (OECD), Genome Research, the National Cancer Institute (NCI), the European Medicines Agency (EMA), the Population Health Research Institute (PHRI), PubMed, the World Bank, and the World Health Organization (WHO), among others. Secondary sources also included corporate and regulatory filings, such as annual reports, SEC filings, investor presentations, and financial statements; business magazines and research journals; press releases; and trade, business, and professional associations. Secondary data were collected and analyzed to determine the overall size of the global next-generation sequencing market, which was validated through primary research.
Primary Research
Extensive primary research was conducted after acquiring basic knowledge of the global next-generation sequencing market through secondary research. Several primary interviews were conducted with market experts from the supply side, including C-level and D-level executives, operational managers, and marketing & sales managers at key manufacturers, distributors, and channel partners of companies providing NGS; and from the demand side, including personnel from academic & research institutes, hospitals, clinics and diagnostic labs, pharmaceutical & biopharmaceutical industries, CROs, and other end users. These interviews were conducted across six major regions, including North America, Europe, the Asia-Pacific, Latin America, the Middle East, and Africa. Approximately 70% and 30% of the primary interviews were conducted with supply-side and demand-side participants, respectively. This primary data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.
The following is a breakdown of the primary respondents:
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
Both, the top-down and bottom-up approaches were used to estimate and validate the total size of the next-generation sequencing market. These methods were also used extensively to estimate the size of various subsegments within the market. The research methodology for estimating market size includes the following.
Data Triangulation
To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Market Definition
Next-generation sequencing (NGS) refers to non-Sanger-based, high-throughput DNA sequencing technologies. These technologies sequence DNA strands simultaneously, yielding substantially higher throughput and reducing the need for fragment-cloning methods often used in Sanger genome sequencing. NGS is fundamentally based on sequencing by synthesis (SBS), ion semiconductor sequencing, single-molecule real-time (SMRT) sequencing, and nanopore sequencing.
Key Stakeholders
- NGS instrument manufacturers, vendors, and distributors
- NGS service providers
- NGS bioinformatics/data analysis companies
- Research laboratories and academic institutes
- Venture capitalists and other government funding organizations
- Research and consulting firms
- Healthcare institutions (hospitals and diagnostic clinics)
- Pharmaceutical and biotechnology companies
- Academic and government research institutes
- Life science companies
Report Objectives
- To define, describe, and forecast the next-generation sequencing market based on offering, product type, platform technology, product workflow, product end user, service type, service workflow, service end user, application, and region
- To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
- To strategically analyze micro markets with respect to individual growth trends, prospects, and contributions to the overall next-generation sequencing market
- To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments with respect to six main regions, namely, North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa
- To profile key players in the global next-generation sequencing market and comprehensively analyze their platforms, reagents, kits, consumables, and service portfolios, market position, and core competencies
- To track and analyze competitive developments such as product & service launches, expansions, agreements, and collaborations in the next-generation sequencing market
- To benchmark players within the next-generation sequencing market using the ‘Company Evaluation Matrix' framework, which analyzes market players based on various parameters within the broad categories of business and service strategy.
Available customizations:
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:
Geographical Analysis
- Further breakdown of the Rest of Europe next-generation sequencing market, by country
- Further breakdown of the Rest of Asia Pacific next-generation sequencing market, by country
- Further breakdown of the Rest of Latin America next-generation sequencing market, by country
- Further breakdown of the Rest of Middle East next-generation sequencing market, by country
Company Information
- Detailed analysis and profiling of additional market players (up to five)
Segment Analysis
- Further breakdown of the other application and other end users area into subsegments
- Cross-segment analysis.
Get the Full Next-generation Sequencing Market Report
Full forecast, segment splits, and company analysis for all Next-generation Sequencing Market.
- Canada Next-generation Sequencing Market
- US Next-generation Sequencing Market
- Germany Next-generation Sequencing Market
- UK Next-generation Sequencing Market
- France Next-generation Sequencing Market
- Italy Next-generation Sequencing Market
- Spain Next-generation Sequencing Market
- Netherlands Next-generation Sequencing Market
- China Next-generation Sequencing Market
- India Next-generation Sequencing Market
- Australia Next-generation Sequencing Market
- South Korea Next-generation Sequencing Market
- Brazil Next-generation Sequencing Market
- Mexico Next-generation Sequencing Market
- Saudi Arabia Next-generation Sequencing Market
- UAE Next-generation Sequencing Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report